Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. The treatment to the treatment of autoimmune diseases is now available in 31 countries.
Remsima, developed by the South Korean company Celltrion, is the world’s first biosimilar monoclonal antibody (mAb) to be approved by the European Medicines Agency (EMA). It is indicated for the treatment of adult and pediatric Crohn’s disease (CD), adult and pediatric ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Furthermore, Remsima is an anti-tumor necrosis factor (anti-TNF) mAb that is used for reducing inflammation and improving other symptoms of the diseases for which it is indicated.
While biologics have positively impacted patient treatment, the high cost of using such drugs places a considerable burden on healthcare systems and can affect patient access to treatment. Biosimilars have the potential to offer cost savings for health services, particularly as they are often used to treat long-term conditions.